MetaCap

CytoMed Therapeutics (GDTC) vs Radiopharm Theranostics (RADX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CytoMed Therapeutics (GDTC) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 59.8% versus a loss of 86.1%. Radiopharm Theranostics is the larger company by market cap ($9.9 million vs $9.0 million), about 1.1 times the size. Radiopharm Theranostics converts more of its revenue into profit, with a net margin of -1055.3% versus -1227.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GDTC-59.84%RADX-86.15%
+145%+24%-97%
Nov 21, 20251 yearNov 20, 2026
GDTC-73.97%RADX-96.66%
+25%-39%-102%
Dec 2, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GDTC versus RADX key metrics
MetricGDTCRADX
Share price$0.755$0.6304
Market cap$9.01M$9.90M
1-day change-2.33%-9.71%
YTD return-43.45%-87.92%
1-year return-59.84%-86.15%
EPS (TTM)$-0.23$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$252.26K$3.63M
Revenue growth (YoY)+395.88%+1114.27%
Net income (latest FY)$-3.10M$-38.34M
Gross margin—1.08%
Operating margin—-1050.63%
Net margin-1227.07%-1055.27%
52-week high$2.12$16.25
52-week low$0.68$0.63
Distance from 52-week high-64.39%-96.12%
Analyst consensusnonestrong_buy
Avg. price target upside+450.99%+2595.11%
Average volume15.69K55.23K
Shares outstanding11.93M15.70M
Employees4214
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GDTC has outperformed RADX by 26.3 percentage points over the past year.
  • Radiopharm Theranostics is more profitable, keeping -1055.3 cents of every revenue dollar as net income versus -1227.1 cents for CytoMed Therapeutics.
  • Radiopharm Theranostics grew revenue faster in its latest fiscal year (+1114.27% vs +395.88%).

About CytoMed Therapeutics

GDTC stock →

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.

Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees

About Radiopharm Theranostics

RADX stock →

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

GDTC vs RADX FAQ

Which is bigger, CytoMed Therapeutics or Radiopharm Theranostics?

Radiopharm Theranostics (RADX) is larger, with a market capitalization of $9.90M compared with $9.01M for CytoMed Therapeutics (GDTC).

Which stock has performed better over the past year, GDTC or RADX?

GDTC returned -59.84% over the past 12 months, compared with -86.15% for RADX (price return, excluding dividends). Past performance does not predict future results.

Are CytoMed Therapeutics and Radiopharm Theranostics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons